Svennilson Peter
Follow13F filer, CIK 1606074, SAN FRANCISCO, CA
Svennilson Peter reported $113,470,000 across 4 holdings for the quarter ended 2018-12-31, in a 13F-HR filed 2019-02-13.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001606074-19-000001
- Period
- 2018-12-31
- Reported value
- $113M
- Holdings
- 4
- Top 10 weight
- 100%
- New
- Sold out
Stakes and trades reported after 2018-12-31
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
Accepted , ingested - TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
Accepted , ingested
Holdings, Q4 2018
Share positions as resolved from 13F-HR 0001606074-19-000001, largest first. % of portfolio is the value over $113,470,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| GRITSTONE BIO INCGRITSTONE BIO INC | 3,102,934 | $47.9M | 42.25% | ||||
| RCUSARCUS BIOSCIENCES INC | 3,540,850 | $38.1M | 33.61% | Timeline | |||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 4,677,938 | $18.8M | 16.53% | ||||
| IMMUNE DESIGN CORP.IMMUNE DESIGN CORP. | 6,642,942 | $8.64M | 7.61% |
How Q4 2018 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001606074-19-000001 | base | 2019-02-13 | acceptance time not in the bulk data set |